<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0cf064d0-cf65-4112-8817-ed864f16233e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use XENPOZYME safely and effectively. See full prescribing information for XENPOZYME.<br/>
      <br/> XENPOZYME<sup>Â®</sup> (olipudase alfa-rpcp) for injection, for intravenous use<br/> Initial U.S. Approval: 2022</title>
   <effectiveTime value="20250303"/>
   <setId root="01a910ee-a33e-4be3-ac41-322d64c34311"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="025322157" root="1.3.6.1.4.1.519.1"/>
            <name>Genzyme Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="968278916" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="108684523" root="1.3.6.1.4.1.519.1"/>
                        <name>Bionique Testing Laboratories, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="147227730" root="1.3.6.1.4.1.519.1"/>
                        <name>Bioreliance Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="985127419" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Ireland Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="050424395" root="1.3.6.1.4.1.519.1"/>
                        <name>Genzyme Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="238239933" root="1.3.6.1.4.1.519.1"/>
                        <name>Eurofins Biopharma Product Testing Ireland Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="965750420" root="1.3.6.1.4.1.519.1"/>
                        <name>Patheon Biologics LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="22311e16-dcb3-4a5e-8296-c37b244cb359"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241224"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58468-0050" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>XENPOZYME</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>olipudase alfa-rpcp</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="5.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6D5766Q4OP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLIPUDASE ALFA</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6D5766Q4OP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OLIPUDASE ALFA</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="4.47" unit="mg"/>
                              <denominator value="5.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="8.17" unit="mg"/>
                              <denominator value="5.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="250" unit="mg"/>
                              <denominator value="5.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="74.6" unit="mg"/>
                              <denominator value="5.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHIONINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5.1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58468-0050-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220829"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761261" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220829"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="58468-0051" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>XENPOZYME</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>olipudase alfa-rpcp</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="4" unit="mg"/>
                              <denominator value="1.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6D5766Q4OP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLIPUDASE ALFA</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6D5766Q4OP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OLIPUDASE ALFA</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.89" unit="mg"/>
                              <denominator value="1.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.63" unit="mg"/>
                              <denominator value="1.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="1.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="14.92" unit="mg"/>
                              <denominator value="1.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHIONINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="58468-0051-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220829"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761261" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220829"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="fae2eaf1-c2be-4c9b-8243-2c6e1d932e8b"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Patients treated with XENPOZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to XENPOZYME may be considered <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="a4bd37ab-a4ee-43b6-923c-a10907bccddb"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration, Missed Doses (<linkHtml href="#S2.4">2.4</linkHtml>)</td>
                                 <td>12/2024</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Administration Instructions (<linkHtml href="#S2.7">2.7</linkHtml>)</td>
                                 <td>12/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="010636ee-7ab8-4222-95ea-a78ea2c96cf2"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>XENPOZYME is indicated for treatment of nonâcentral nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. </paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>XENPOZYME is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of nonâcentral nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="f7904ff2-6a5c-4e81-8d09-78587980a949"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>See Full Prescribing Information for important recommendations prior to XENPOZYME treatment initiation. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Adults: Recommended starting dose is 0.1 mg/kg administered as an intravenous infusion. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Pediatrics: Recommended starting dose is 0.03 mg/kg administered as an intravenous infusion. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>See Full Prescribing Information for the recommended dose escalation and maintenance dosage, dosage modifications to reduce the risk of adverse reactions, and preparation and administration instructions. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S2.6">2.6</linkHtml>, <linkHtml href="#S2.7">2.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="d8c83d3c-ca08-4940-a7b7-d0c9162e5cea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Recommendations Prior to XENPOZYME Treatment Initiation </title>
                     <text>
                        <paragraph>
								Therapy with XENPOZYME should be directed in consultation with physicians knowledgeable in the management of ASMD. In order to avoid dosing errors including overdosage <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>, follow all instructions for dosage and administration.
								</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="739c3dd7-cf6f-4c37-af02-9ff1ce4cbf04"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Testing</content>
                              </paragraph>
                              <paragraph>Before initiating XENPOZYME:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Obtain baseline transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) levels in all patients within 1 month prior to treatment initiation <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>. 											</item>
                                 <item>Verify pregnancy status in females of reproductive potential <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>,<linkHtml href="#S8.3"> 8.3)</linkHtml>]</content>. 											</item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0ccf759a-6f1d-4651-9353-d8bc3e48658a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Premedication</content>
                              </paragraph>
                              <paragraph>Prior to XENPOZYME administration, consider premedicating with antihistamines, antipyretics, and/or corticosteroids <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2)</linkHtml>]</content>. 										</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="424c196a-ef69-415c-ad82-218df07c9488"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Medical Support</content>
                              </paragraph>
                              <paragraph>Appropriate medical support measures including cardiopulmonary resuscitation equipment should be readily available during XENPOZYME administration <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6299d3b4-3389-4bb3-942d-9c7248600780"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Weight-Based Dosing Information</content>
                              </paragraph>
                              <paragraph>The recommended adult and pediatric dosages of XENPOZYME for the dose escalation and maintenance phases <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content> are based on body weight as follows for patients with a body mass index (BMI):</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Less than or equal to 30, the dosage is based on actual body weight (kg)</item>
                                 <item>Greater than 30, the dosage is based on adjusted body weight (kg). Calculate an adjusted body weight (kg) based on height in meters as described below:<list listType="unordered">
                                       <item>
                                          <caption>Â </caption>Adjusted body weight (kg) = (actual height in m)<sup>2</sup> Ã 30</item>
                                    </list>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="a2383ba5-3f1f-4999-b57e-e8c0b40f5b4f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 	Recommended Dosage in Adult Patients </title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="70da411e-34a3-4c2f-979a-22318e24ce20"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dose Escalation Phase</content>
                              </paragraph>
                              <paragraph>The recommended starting dose of XENPOZYME in adults is 0.1 mg/kg.</paragraph>
                              <paragraph>In order to reduce the risk of infusion-associated reactions or elevated transaminase levels, follow the dose escalation regimen in Table 1 <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>.</paragraph>
                              <paragraph>Administer XENPOZYME via intravenous infusion every 2 weeks. 										</paragraph>
                              <table width="90%" ID="table1">
                                 <caption>Table 1: XENPOZYME Dose Escalation Regimen for Adult Patients<footnote>Use actual body weight for patients with a BMI less than or equal to 30. For patients with a BMI greater than 30, calculate adjusted body weight (kg) = (actual height in m)<sup>2</sup> Ã 30 <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>. </footnote>
                                 </caption>
                                 <col width="50%" align="left" valign="middle"/>
                                 <col width="50%" align="left" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule">Adult Patients (18 years and older)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">First dose (Day 1/Week 0)</td>
                                       <td styleCode="Rrule">0.1 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Second dose (Week 2)</td>
                                       <td styleCode="Rrule">0.3 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Third dose (Week 4)</td>
                                       <td styleCode="Rrule">0.3 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fourth dose (Week 6)</td>
                                       <td styleCode="Rrule">0.6 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fifth dose (Week 8)</td>
                                       <td styleCode="Rrule">0.6 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sixth dose (Week 10)</td>
                                       <td styleCode="Rrule">1 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Seventh dose (Week 12)</td>
                                       <td styleCode="Rrule">2 mg/kg</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Eighth dose (Week 14)<footnote>The dose escalation phase includes the first 3 mg/kg dose.</footnote>
                                       </td>
                                       <td styleCode="Rrule">3 mg/kg (recommended maintenance dose)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1456c060-4600-4f4c-8c22-7ffa3e5b9b98"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Maintenance Phase</content>
                              </paragraph>
                              <paragraph>The recommended maintenance dosage of XENPOZYME in adults is 3 mg/kg via intravenous infusion every 2 weeks. </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="2a939cb3-fb28-4430-9807-59f70432b1b0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 	Recommended Dosage in Pediatric Patients</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="7e3044ca-ecc4-49e1-86ed-d316484b92a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dose Escalation Phase</content>
                              </paragraph>
                              <paragraph>The recommended starting dose of XENPOZYME in pediatric patients is 0.03 mg/kg. </paragraph>
                              <paragraph>In order to reduce the risk of hypersensitivity and infusion-associated reactions or elevated liver enzyme elevations, follow the dose escalation regimen in Table 2 <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>. </paragraph>
                              <paragraph>Administer XENPOZYME via intravenous infusion every 2 weeks.</paragraph>
                              <table width="90%" ID="table2">
                                 <caption>Table 2: XENPOZYME Dose Escalation Regimen for Pediatric Patients<footnote>Use actual body weight for patients with a BMI less than or equal to 30. For patients with a BMI greater than 30, calculate adjusted body weight (kg) = (actual height in m)<sup>2</sup> Ã 30 <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</footnote>
                                 </caption>
                                 <col width="50%" align="left" valign="middle"/>
                                 <col width="50%" align="left" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th colspan="2" align="center" styleCode="Lrule Rrule">Pediatric Patients (0 to 17 years)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">First dose (Day 1/Week 0)</td>
                                       <td styleCode="Rrule">0.03 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Second dose (Week 2)</td>
                                       <td styleCode="Rrule">0.1 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Third dose (Week 4)</td>
                                       <td styleCode="Rrule">0.3 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fourth dose (Week 6)</td>
                                       <td styleCode="Rrule">0.3 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fifth dose (Week 8)</td>
                                       <td styleCode="Rrule">0.6 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sixth dose (Week 10)</td>
                                       <td styleCode="Rrule">0.6 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Seventh dose (Week 12)</td>
                                       <td styleCode="Rrule">1 mg/kg</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Eighth dose (Week 14)</td>
                                       <td styleCode="Rrule">2 mg/kg</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Ninth dose (Week 16)<footnote>The dose escalation phase includes the first 3 mg/kg dose.</footnote>
                                       </td>
                                       <td styleCode="Rrule">3 mg/kg (recommended maintenance dose)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a39192c8-d771-4284-b119-89c6bb135e81"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Maintenance Phase</content>
                              </paragraph>
                              <paragraph>The recommended maintenance dosage of XENPOZYME in pediatric patients is 3 mg/kg via intravenous infusion every 2 weeks.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="b9a2fcf7-cef1-4a7a-86ed-aa091f0fdf1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 	Missed Doses </title>
                     <text>
                        <paragraph>A dose is considered missed when it is not administered within 3 days of the scheduled date. When a dose of XENPOZYME is missed, refer to Table 3. Follow the instructions in the "Escalation Phase" or "Maintenance Phase" depending on which phase the patient misses the dose.</paragraph>
                        <table width="100%">
                           <caption>Table 3: Dosing Recommendations for XENPOZYME Missed Doses<footnote>At scheduled infusion after a missed dose, if the dose administered is 0.3 or 0.6 mg/kg, administer that dose twice as per Table 1 and 2.</footnote>
                           </caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center" valign="middle">Consecutive Missed Doses In:</th>
                                 <th styleCode="Rrule" align="center" valign="middle">Escalation Phase</th>
                                 <th styleCode="Rrule" align="center" valign="middle">Maintenance Phase</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1 missed dose</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>First dose after a missed dose: Administer last tolerated dose</item>
                                       <item>Second and subsequent doses after missed dose: Resume dose escalation at next infusion according to Table 1 for adult patients or Table 2 for pediatric patients</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">First and subsequent doses after missed dose: Administer maintenance dose</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">2 consecutive missed doses</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>First dose after missed dose: Administer 1 dose below last tolerated dose </item>
                                       <item>Second and subsequent doses after missed dose: Resume dose escalation according to Table 1 for adults or Table 2 for pediatric patients</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>First dose after missed dose: Administer 1 dose below the maintenance dose </item>
                                       <item>Second and subsequent doses after missed dose: Resume the maintenance dose</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="xmChange">3 or more consecutive missed doses</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered">
                                       <item>For adult patients who have not completed the dose escalation phase: Reinitiate dose escalation regimen starting at 0.1 mg/kg and follow Table 1.</item>
                                       <item>For pediatric patients who have not completed the dose escalation phase: Reinitiate dose escalation regimen starting at 0.03 mg/kg and follow Table 2.</item>
                                    </list>
                                 </td>
                                 <td styleCode="Rrule">First and subsequent doses after missed doses: Restart dosing at 0.3 mg/kg and follow Table 1 for adult patients or Table 2 for pediatric patients.<list listType="unordered">
                                       <item>For adult patients who have missed 3 or more consecutive doses in the mainenance phase during which sphingomyelin could have reaccumulated: The treating physician may consider resuming dosing at 0.1 mg/kg and dose escalate according to Table 1.</item>
                                       <item>For pediatric patients who have missed 3 or more consecutive doses in the maintenance phase during which sphingomyelin could have reaccumulated: The treating physician may consider resuming dosing at 0.03 mg/kg and dose escalate according to Table 2.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="3fdff74b-cbe9-4332-9c15-caf8b4173c2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 	Dosage and Administration Modifications and Monitoring </title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>In the event of a <content styleCode="italics">severe</content> hypersensitivity reaction (e.g., anaphylaxis) or a <content styleCode="italics">severe</content> infusion-associated reaction (IAR), immediately discontinue XENPOZYME administration and initiate appropriate medical treatment <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2)</linkHtml>]</content>. </item>
                           <item>In the event of a <content styleCode="italics">mild to moderate</content> hypersensitivity reaction or a <content styleCode="italics">mild to moderate</content> IAR, consider temporarily holding or slowing the infusion rate, and/or reducing the XENPOZYME dose. If dose is reduced, re-escalate following dose escalation described in Tables 1 and 2 for adult and pediatric patients, respectively <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2)</linkHtml>]</content>. </item>
                           <item>If transaminase levels are elevated above baseline and &gt;2 times the ULN prior to the next scheduled administration, the XENPOZYME dose can be adjusted (prior dose repeated or reduced) or treatment can be temporarily withheld until the liver transaminases return to the patient's baseline value <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="cf7e3bca-ac13-4b15-b2cf-c28950cbc1b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 	Preparation Instructions </title>
                     <text>
                        <paragraph>Use aseptic technique during preparation. Reconstitute and dilute XENPOZYME in the following manner:</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="77219fcc-0c86-44d8-8d52-b62a68593d81"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Reconstitution and Dilution Instructions</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>1.</caption> Determine the number of XENPOZYME vials to be reconstituted based on the calculated dose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>. </item>
                                 <item>
                                    <caption>2.</caption> Remove XENPOZYME vials from refrigeration and set aside for approximately 20 to 30 minutes to allow vials to reach room temperature.</item>
                                 <item>
                                    <caption>3.</caption> Reconstitute each vial with:<list listType="unordered" styleCode="disc">
                                       <item>1.1 mL of Sterile Water for Injection, USP into the 4 mg vial</item>
                                       <item>5.1 mL of Sterile Water for Injection, USP into the 20 mg vial</item>
                                    </list>
                                    <list listType="ordered">
                                       <item>
                                          <caption>Â </caption>by directing the diluent flow to the inside wall of the vial to avoid foaming.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>4.</caption> Gently roll and tilt vial(s) to reconstitute XENPOZYME and avoid foaming. Each reconstituted vial will yield a 4 mg/mL clear, colorless solution.</item>
                                 <item>
                                    <caption>5.</caption> Visually inspect the reconstituted solution in the vials for particulate matter and discoloration. The solution should be clear and colorless. Discard if the solution is discolored or if visible particulate matter is present. </item>
                                 <item>
                                    <caption>6.</caption> Withdraw the required volume of XENPOZYME from the vial(s) and dilute the XENPOZYME solution for infusion with 0.9% Sodium Chloride Injection, USP in a syringe or infusion bag depending on the volume of infusion (see <linkHtml href="#table4">Table 4</linkHtml>).<list listType="unordered" styleCode="disc">
                                       <item>For patients who weigh less than 10 kg receiving 0.03 mg/kg and 0.1 mg/kg and patients who weigh between 10 to 20 kg receiving 0.03 mg/kg dose, the volume of infusion will vary to achieve a fixed final concentration of 0.1 mg/mL (see <linkHtml href="#table4">Table 4</linkHtml>). Prepare the required dose diluted to a final concentration of 0.1 mg/mL in a <content styleCode="italics">syringe</content> for infusion. </item>
                                       <item>For all other patient weights and doses, the final concentration will vary to achieve a fixed total volume (see <linkHtml href="#table4">Table 4</linkHtml>).</item>
                                    </list>
                                    <list listType="unordered">
                                       <item>
                                          <caption>-</caption>For total volume less than or equal to 20 mL prepare a <content styleCode="italics">syringe</content> for infusion:<list listType="unordered" styleCode="circle">
                                             <item>Inject the required volume of the reconstituted XENPOZYME solution (4 mg/mL) from step 3 slowly down the inside wall of the syringe.</item>
                                             <item>Add slowly the quantity sufficient of 0.9% Sodium Chloride Injection, USP to obtain the required total infusion volume (avoid foaming within the syringe). </item>
                                          </list>
                                       </item>
                                       <item>
                                          <caption>-</caption>For a total volume of greater than or equal to 50 mL prepare an <content styleCode="italics">infusion bag</content>:<list listType="unordered">
                                             <item>
                                                <caption>Â </caption>Add slowly the required volume of the reconstituted XENPOZYME solution (4 mg/mL) from step 3 into the appropriate size 0.9% Sodium Chloride Injection, USP infusion bag (avoid foaming within the bag) to achieve a fixed total volume per Table 4.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>7.</caption> Gently invert the syringe or the infusion bag to mix. Do not shake. Because this is a protein solution, slight flocculation (described as thin translucent fibers) occurs occasionally after dilution.</item>
                                 <item>
                                    <caption>8.</caption> Vials are for single dose only. Discard any unused solution.</item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="11dd7456-6c05-40e1-ad60-27b29610f56e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Storage and Handling of the Reconstituted and Diluted Solutions</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>If the reconstituted XENPOZYME vials are not used immediately, store refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) for up to 24 hours or at controlled room temperature at 20Â°C to 25Â°C (68Â°F to 77Â°F) for up to 6 hours. Discard the unused XENPOZYME reconstituted solution after 24 hours if stored refrigerated or 6 hours if stored at controlled room temperature.</item>
                                 <item>If the diluted solution is not used immediately, refrigerate the diluted solution at 2Â°C to 8Â°C (36Â°F to 46Â°F) for up to 24 hours or store at room temperature at 20Â°C to 25Â°C (68Â°F to 77Â°F) for up to 12 hours (inclusive of infusion time), or discard.</item>
                                 <item>Do not freeze.</item>
                              </list>
                              <table width="100%" ID="table4">
                                 <caption>Table 4: XENPOZYME Infusion Volumes for Pediatric and Adult Patients Based on Body Weight<footnote>Use actual or adjusted body weight per patient BMI. Refer to section 2. <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>.</footnote>
                                 </caption>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="3" valign="middle">Pediatric Patients (0 to 17 years)</th>
                                       <th styleCode="Rrule">Adult patients (18 years and older)</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Body Weight<br/>â¥2 kg and &lt;10 kg</th>
                                       <th styleCode="Rrule">Body Weight<br/>â¥10 kg and &lt;20 kg</th>
                                       <th styleCode="Rrule">Body Weight<br/>â¥20 kg</th>
                                       <th styleCode="Rrule">Body Weight<br/>â¥20 kg</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">XENPOZYME Dose</th>
                                       <th styleCode="Rrule" colspan="4" valign="middle">Total Infusion Volume</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">0.03 mg/kg</td>
                                       <td styleCode="Rrule">Actual volume will vary<footnote ID="t4f1">Volume will vary to achieve a final concentration of 0.1 mg/mL</footnote>
                                          <br/>(0.6 mL to 3 mL)</td>
                                       <td styleCode="Rrule">Actual volume will vary<footnoteRef IDREF="t4f1"/>
                                          <br/>(3 mL to 6 mL)</td>
                                       <td styleCode="Rrule">5 mL</td>
                                       <td styleCode="Rrule">NA</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">0.1 mg/kg</td>
                                       <td styleCode="Rrule">Actual volume will vary<footnoteRef IDREF="t4f1"/>
                                          <br/>(2 mL to 10 mL)</td>
                                       <td styleCode="Rrule">5 mL</td>
                                       <td styleCode="Rrule">10 mL</td>
                                       <td styleCode="Rrule">20 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">0.3 mg/kg</td>
                                       <td styleCode="Rrule">5 mL</td>
                                       <td styleCode="Rrule">10 mL</td>
                                       <td styleCode="Rrule">20 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">0.6 mg/kg</td>
                                       <td styleCode="Rrule">10 mL</td>
                                       <td styleCode="Rrule">20 mL</td>
                                       <td styleCode="Rrule">50 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">1 mg/kg</td>
                                       <td styleCode="Rrule">20 mL</td>
                                       <td styleCode="Rrule">50 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">2 mg/kg</td>
                                       <td styleCode="Rrule">50 mL</td>
                                       <td styleCode="Rrule">75 mL</td>
                                       <td styleCode="Rrule">200 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">3 mg/kg</td>
                                       <td styleCode="Rrule">50 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                       <td styleCode="Rrule">250 mL</td>
                                       <td styleCode="Rrule">100 mL</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="f7fbc6f6-8541-443a-859f-02de9977f0bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 	Administration Instructions </title>
                     <text>
                        <list listType="ordered" styleCode="arabic">
                           <item>Prior to administration, inspect the syringe or infusion bag for foaming. If foaming is present, let foam dissipate before administering XENPOZYME.</item>
                           <item>Use a low-protein binding, 0.2 micron, in-line filter during administration. The following materials can be used: polyolefin or polyvinylchloride (PVC) with DEHP for infusion bags, polypropylene for syringes, polyurethane or PVC DEHP-free for infusion sets and polyethersulfone or polytetrafluoroethylene for in-line filters. </item>
                           <item>Infuse XENPOZYME using the infusion rates described in Table 5 and Table 6. In absence of infusion-associated reactions, increase infusion rate per the steps of infusion as indicated (+/- 5 minutes). Each step of infusion will last for 20 minutes with the exception of the final step which should last until completion of the infusion volume.</item>
                           <item>At the end of the infusion, flush the infusion line with 0.9% Sodium Chloride Injection, USP using the same infusion rate as the one used for the last part of the infusion.</item>
                           <item>Do not infuse XENPOZYME in the same intravenous line with other products.</item>
                        </list>
                        <table width="75%">
                           <caption>Table 5: XENPOZYME Infusion Rates for Adult Patients</caption>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule">Dose</th>
                                 <th styleCode="Rrule" colspan="4">Infusion Rate</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">step 1</th>
                                 <th styleCode="Rrule">step 2</th>
                                 <th styleCode="Rrule">step 3</th>
                                 <th styleCode="Rrule">step 4</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left">NA: Not applicable.</td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left">Start infusion at step 1 and in absence of infusion-associated reaction increase infusion rate sequentially per the steps of infusion. </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">0.1 mg/kg</td>
                                 <td styleCode="Rrule">20 mL/hour</td>
                                 <td styleCode="Rrule">60 mL/hour</td>
                                 <td styleCode="Rrule">NA</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">0.3 to 3 mg/kg</td>
                                 <td styleCode="Rrule">3.33 mL/hour</td>
                                 <td styleCode="Rrule">10 mL/hour</td>
                                 <td styleCode="Rrule">20 mL/hour</td>
                                 <td styleCode="Rrule">33.33 mL/hour</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="75%">
                           <caption>Table 6: XENPOZYME Infusion Rates for Pediatric Patients</caption>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" rowspan="2">Dose</th>
                                 <th styleCode="Rrule" colspan="4">Infusion rate</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule">step 1</th>
                                 <th styleCode="Rrule">step 2</th>
                                 <th styleCode="Rrule">step 3</th>
                                 <th styleCode="Rrule">step 4</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left">NA: Not applicable.</td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left">Start infusion at step 1 and in absence of infusion-associated reactions increase infusion rate sequentially per the steps of infusion.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.03 mg/kg</td>
                                 <td styleCode="Rrule">0.1 mg/kg/hour for the full length of the infusion </td>
                                 <td styleCode="Rrule">NA</td>
                                 <td styleCode="Rrule">NA</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.1 mg/kg</td>
                                 <td styleCode="Rrule">0.1 mg/kg/hour </td>
                                 <td styleCode="Rrule">0.3 mg/kg/hour </td>
                                 <td styleCode="Rrule">NA</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.3 mg/kg</td>
                                 <td styleCode="Rrule">0.1 mg/kg/hour </td>
                                 <td styleCode="Rrule">0.3 mg/kg/hour</td>
                                 <td styleCode="Rrule">0.6 mg/kg/hour</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.6 mg/kg</td>
                                 <td styleCode="Rrule Botrule" rowspan="4">0.1 mg/kg/hour </td>
                                 <td styleCode="Rrule Botrule" rowspan="4">0.3 mg/kg/hour </td>
                                 <td styleCode="Rrule Botrule" rowspan="4">0.6 mg/kg/hour </td>
                                 <td styleCode="Rrule Botrule" rowspan="4">1 mg/kg/hour </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1 mg/kg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">2 mg/kg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">3 mg/kg</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="1591b869-a6be-4ffc-80c9-43038e9d7ed5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Home Infusion</content>
                              </paragraph>
                              <paragraph>Home administration under the supervision of a healthcare provider may be considered for patients on maintenance dose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content> and who are tolerating their infusion well. The decision to have patients moved to home infusion should be made after evaluation and recommendation by a physician.</paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The dose and infusion rate used in the home setting should remain the same as were used in the supervised clinical setting and should not be changed without supervision of a physician. In case of missed dose(s) or delayed infusion, contact a physician as subsequent infusions may occur in a supervised clinical setting.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3f9cb62b-a6f3-4ee7-bb33-75bb4454ade5"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>For injection: 4 mg or 20 mg of olipudase alfa-rpcp as a sterile, white to off white lyophilized powder in a single-dose vial for reconstitution.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 4 mg or 20 mg of olipudase alfa-rpcp as a lyophilized powder in a single-dose vial for reconstitution. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="e2af4d8f-c232-4381-90f1-b90a31c70589"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="27e31035-94e9-477c-b27a-75c4dafc8933"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Infusion-Associated Reactions (IARs):</content> If severe IARs occur, discontinue XENPOZYME and initiate appropriate medical treatment. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Elevated Transaminases:</content> Assess ALT and AST within one month prior to initiation of XENPOZYME, within 72 hours prior to any infusion during dose escalation, or prior to the next scheduled XENPOZYME infusion upon resuming treatment following a missed dose. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Risk of Fetal Malformations During Dosage Initiation or Escalation in Pregnancy:</content> XENPOZYME dosage initiation or escalation, at any time during pregnancy, is not recommended as it may lead to elevated sphingomyelin metabolite levels that may increase the risk of fetal malformations. Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if XENPOZYME is discontinued. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="6924e065-599f-4000-b8f7-5f3c34e400df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Hypersensitivity Reactions Including Anaphylaxis</title>
                     <text>
                        <paragraph>Life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in olipudase alfa-treated patients. One 18-month-old XENPOZYME-treated patient experienced an anaphylactic reaction during the sixth infusion in the dose escalation period in Trial 2 <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Additionally, a 16-month-old patient with ASMD type A, treated with a version of olipudase alfa manufactured from a different process, experienced two anaphylactic reactions during the fifth and sixth infusions in the dose escalation period; the patient received an immune tolerance induction therapy prior to treatment. In both of these pediatric patients with anaphylaxis, anti-olipudase alfa-rpcp IgE (IgE ADA) and IgG (IgG ADA) antibodies were detected <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S12.6">Clinical Pharmacology (12.6)</linkHtml>]</content>. 								</paragraph>
                        <paragraph>Hypersensitivity reactions that were mild to moderate in severity occurred in 10 (33%) XENPOZYME-treated adult patients and 4 (50%) XENPOZYME-treated pediatric patients in clinical trials. Hypersensitivity reactions in adults included urticaria, pruritus, erythema, rash, rash erythematous, eczema, angioedema, and erythema nodosum. Hypersensitivity reactions in pediatric patients included urticaria, pruritus, rash, erythema, and localized edema <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                        <paragraph>Prior to XENPOZYME administration, consider premedicating with antihistamines, antipyretics, and/or corticosteroids. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. </paragraph>
                        <list listType="unordered">
                           <item>If a <content styleCode="italics">severe</content> hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. Consider the risks and benefits of re-administering XENPOZYME following a severe hypersensitivity reaction (including anaphylaxis). One patient has been rechallenged using slower infusion rates at a dosage lower than the recommended dosage. In patients with a severe hypersensitivity reaction, a tailored desensitization procedure to XENPOZYME may be considered. If the decision is made to readminister XENPOZYME, ensure the patient tolerates the infusion. If the patient tolerates the infusion, the dosage (dose and/or the rate) may be increased to reach the recommended dosage.<list listType="unordered">
                                 <item>Consider testing for IgE ADA in XENPOZYME-treated patients who experienced severe hypersensitivity reactions, including anaphylaxis [<content styleCode="italics">see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                                    </content>]. Testing for antibodies against olipudase alfa-rpcp are available through Genzyme Corporation (at 1-800-745-4447). Consider other clinical laboratory testing such as serum tryptase and complement activation in patients who experience anaphylaxis.</item>
                              </list>
                           </item>
                           <item>If a <content styleCode="italics">mild or moderate</content> hypersensitivity reaction occurs, consider temporarily holding the infusion, slowing the infusion rate, and/or reducing the XENPOZYME dose <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2dfdfe00-e0a9-423d-b932-913425080c43"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 	Infusion-Associated Reactions </title>
                     <text>
                        <paragraph>IARs occurred in approximately 75% of pediatric and 50% of adult XENPOZYME-treated patients in the clinical trials; a severe IAR occurred in one (12.5%) of the pediatric patients. The most frequent IARs in:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>â¥10% of adult patients were headache, pruritus, vomiting, and urticaria</item>
                           <item>&gt;20% of pediatric patients were urticaria, erythema, headache, nausea, pyrexia, and vomiting</item>
                        </list>
                        <paragraph>
									Acute phase reaction (APR), an acute inflammatory response accompanied by elevations in inflammatory serum protein concentrations, was observed in one XENPOZYME-treated adult and one XENPOZYME-treated pediatric patient. Most of the APRs occurred at 48 hours post infusion during the dose escalation period. Elevations of C-reactive protein, calcitonin, and IL-6, and reduction of serum iron were observed. The most common clinical symptoms associated with APRs were pyrexia, vomiting, and diarrhea. Acute phase reactions were managed similar to other IARs. In the postmarketing setting, 24 hours after receiving XENPOZYME at a higher than recommended initial dose, a 2-year-old male patient with ASMD, experienced fever, respiratory distress, hypotension, and death <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>.
								</paragraph>
                        <paragraph>
									Prior to XENPOZYME administration, consider pre-medicating with antihistamines, antipyretics, and/or corticosteroids to reduce the risk of infusion-associated reactions (IARs). However, IARs may still occur in patients after receiving pre-treatment. Follow the dose escalation regimen to minimize IARs <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage &amp; Administration (2.2</linkHtml> &amp; <linkHtml href="#S2.3">2.3)</linkHtml>]</content>.
								</paragraph>
                        <list listType="unordered">
                           <item>If a <content styleCode="italics">severe</content> IAR occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. Consider the risks and benefits of re-administering XENPOZYME following a severe IAR. One patient has been rechallenged using slower infusion rates at a dosage lower than the recommended dosage. If the patient tolerates the infusion, the dosage (dose and/or the rate) may be increased to reach the recommended dosage.</item>
                           <item>If a <content styleCode="italics">mild or moderate</content> IAR occurs, consider temporarily holding the infusion, slowing the infusion rate, and/or reducing the XENPOZYME dosage <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="19e18713-b71f-4ebc-ba84-c8f9787fad66"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 	Elevated Transaminase Levels </title>
                     <text>
                        <paragraph>XENPOZYME may be associated with elevated transaminases (ALT, AST, or both) within 24 to 48 hours after infusion. Elevated transaminase levels were reported in 4 (13%) XENPOZYME-treated adults and 1 (13%) XENPOZYME-treated pediatric patient during the dose escalation phase in clinical trials. At the time of the next scheduled infusion, these elevated transaminase levels generally returned to levels observed prior to the XENPOZYME infusion <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>To manage the risk of elevated transaminase levels, assess ALT and AST within one month prior to initiation of XENPOZYME, within 72 hours prior to any infusion during dose escalation, which includes the first 3 mg/kg dose outlined in Tables 1 and 2, or prior to the next scheduled XENPOZYME infusion upon resuming treatment following a missed dose.</paragraph>
                        <paragraph>If either the baseline or pre-infusion transaminase level (during the dose escalation phase) is &gt;2 times the ULN, repeat transaminase levels within 72 hours after the end of the infusion. If the pre-infusion transaminase levels are elevated above baseline and &gt;2 times the ULN prior to the next scheduled administration, the XENPOZYME dose can be reduced (repeat prior lower dose or reduce the dose) or XENPOZYME can be temporarily withheld until the liver transaminases return to the patient's baseline value.</paragraph>
                        <paragraph>Upon reaching the recommended maintenance dose, transaminase testing is recommended to be continued as part of routine clinical management of ASMD.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="879d63a7-273f-4360-9505-608de337dbb9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 	Risk of Fetal Malformations During Dosage Initiation or Escalation in Pregnancy </title>
                     <text>
                        <paragraph>There is no evidence that olipudase alfa-rpcp crosses the human placenta. However, published literature reports that early embryonic exposure to a metabolite of sphingomyelin (ceramide) or the S1P receptor modulator fingolimod can produce exencephaly in chicks and mice, respectively. In animal reproduction studies, exencephaly, a neural tube defect occurring in the first trimester of pregnancy, was observed in mouse fetuses at exposures less than the exposure at the maximum recommended human dose of olipudase alfa-rpcp.</paragraph>
                        <paragraph>XENPOZYME dosage initiation or escalation, at any time during pregnancy, is not recommended as it may lead to elevated sphingomyelin metabolite levels that may increase the risk of fetal malformations <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Population (8.1)</linkHtml>, <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. The decision to continue or discontinue XENPOZYME maintenance dosing in pregnancy should consider the female's need for XENPOZYME, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal ASMD disease.</paragraph>
                        <paragraph>Verify the pregnancy status in females of reproductive potential prior to initiating XENPOZYME treatment. Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if XENPOZYME is discontinued <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="c68632a9-3c30-415e-a873-f03eac9aa229"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hypersensitivity Reactions Including Anaphylaxis <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Infusion-Associated Reactions (IARs) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Elevated Transaminase Levels <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241224"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Most common adverse reactions in adult patients (incidence â¥10%) are headache, cough, diarrhea, hypotension, and ocular hyperemia. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>Most common adverse reactions in pediatric patients (incidence â¥20%) are pyrexia, cough, diarrhea, rhinitis, abdominal pain, vomiting, headache, urticaria, nausea, rash, arthralgia, pruritus, fatigue, and pharyngitis. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="696ec20b-35ed-460e-8140-1caa2a97057e"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety analysis from 3 clinical trials included a total of 38 XENPOZYME-treated patients (30 adult and 8 pediatric patients) with age range from 1.5 to 59 years old receiving intravenous doses up to 3 mg/kg every 2 weeks <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. The median exposure duration was 2.5 years (range: 0.4 to 3.7 years) in adult patients and 2.7 years (range: 2.5 to 3.2 years) in pediatric patients.</paragraph>
                        <paragraph>Serious adverse reactions of anaphylactic reaction were reported in 2 (25%) XENPOZYME-treated pediatric patients.</paragraph>
                        <paragraph>Most frequently reported adverse drug reactions in adults (incidence â¥10%) were headache, cough, diarrhea, hypotension, and ocular hyperemia.</paragraph>
                        <paragraph>Most frequently reported adverse drug reactions in pediatric patients (incidence â¥20%) were pyrexia, cough, diarrhea, rhinitis, abdominal pain, vomiting, headache, urticaria, nausea, rash, arthralgia, pruritus, fatigue, and pharyngitis.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="600f62b2-1928-4453-a193-1ff860d15b60"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adult patients with ASMD type B and type A/B (Trial 1)</content>
                              </paragraph>
                              <paragraph>In Trial 1, 13 adult patients received XENPOZYME once every 2 weeks for 52 weeks (primary analysis period (PAP)) at dosages escalating from 0.1 mg/kg to a target dose of 3 mg/kg <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>Adverse reactions that occurred in at least 7% of  XENPOZYME-treated adult patients during the PAP are described in Table 7.</paragraph>
                              <table width="75%">
                                 <caption>Table 7: Adverse Reactions Occurring at &gt;7% in Adult Patients with ASMD During the 52-Week Primary Analysis Period in Trial 1</caption>
                                 <col width="40%" align="left" valign="middle"/>
                                 <col width="30%" align="left" valign="middle"/>
                                 <col width="30%" align="left" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th styleCode="Rrule">XENPOZYME<br/>N=13</th>
                                       <th styleCode="Rrule">Placebo<br/>N=18</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">7 (54%)</td>
                                       <td styleCode="Rrule">8 (44%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">4 (31%)</td>
                                       <td styleCode="Rrule">2 (11%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">2 (15%)</td>
                                       <td styleCode="Rrule">2 (11%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension</td>
                                       <td styleCode="Rrule">2 (15%)</td>
                                       <td styleCode="Rrule">2 (11%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Ocular hyperemia</td>
                                       <td styleCode="Rrule">2 (15%)</td>
                                       <td styleCode="Rrule">1 (6%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Erythema</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">1 (6%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Asthenia</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">1 (6%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pharyngitis</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">1 (6%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspnea</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Urticaria</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Papule</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Myalgia</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Throat irritation</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">C-reactive protein abnormal</td>
                                       <td styleCode="Rrule">1 (8%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fb9c3cb2-4dd6-40f1-8807-91409923812c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric Patients with ASMD type B and type A/B (Trial 2 and Trial 3)</content>
                              </paragraph>
                              <paragraph>In Trial 2, 8 pediatric patients less than or equal to 17 years of age received XENPOZYME intravenously once every 2 weeks for 64 weeks <content styleCode="italics">[see <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>. After 64 weeks, all pediatric patients entered into Trial 3.</paragraph>
                              <paragraph>Adverse reactions that occurred in at least 13% of pediatric patients are described in Table 8.</paragraph>
                              <table width="60%">
                                 <caption>Table 8: Adverse Reactions Occurring at â¥13% in XENPOZYME-Treated Pediatric Patients with ASMD in Trial 2<footnote>Duration of treatment in Trial 2 was 64 weeks. All patients continued into Trial 3. </footnote> and Trial 3 for an Overall Observation Period of 2.5 to 3.2 Years</caption>
                                 <col width="60%" align="left" valign="middle"/>
                                 <col width="40%" align="left" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="top">Adverse Reactions</th>
                                       <th styleCode="Rrule">XENPOZYME<br/>N=8</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="2">Abdominal pain includes abdominal pain and abdominal pain upper</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2">Fatigue includes fatigue and asthenia</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2">Rash includes rash and erythema</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pyrexia</td>
                                       <td styleCode="Rrule">8 (100%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">6 (75%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea </td>
                                       <td styleCode="Rrule">6 (75%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rhinitis</td>
                                       <td styleCode="Rrule">6 (75%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal pain</td>
                                       <td styleCode="Rrule">5 (63%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">4 (50%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">4 (50%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Urticaria</td>
                                       <td styleCode="Rrule">4 (50%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">3 (38%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash</td>
                                       <td styleCode="Rrule">3 (38%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Arthralgia</td>
                                       <td styleCode="Rrule">3 (38%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">2 (25%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">2 (25%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pharyngitis</td>
                                       <td styleCode="Rrule">2 (25%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C-reactive protein increased</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anaphylactic reaction</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypersensitivity</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Infusion site swelling</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tachycardia</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Pharyngeal swelling</td>
                                       <td styleCode="Rrule">1 (13%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Treatment related serious adverse reactions, hypersensitivity reactions including anaphylaxis, and IARs occurred within 24 hours of infusion and were observed in a higher percentage of pediatric patients than in adult patients.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e4fa1328-0ead-4570-9c15-fd76c044ac2e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Adverse Reaction</content>
                              </paragraph>
                              <paragraph>Elevated transaminase levels ranging from 3 times to 14 times the upper limit of normal (ULN) were reported in 4 (13%) adults and 1 (13%) pediatric patient during the XENPOZYME dose escalation phase in clinical trials.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6df5d6f1-13a1-49b9-8813-846a1c65afe8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immunogenicity: Antidrug Antibody-Associated Adverse Reactions</content>
                              </paragraph>
                              <paragraph>In Trial 1, infusion-associated reactions (including hypersensitivity reactions) occurred in a higher percentage in XENPOZYME-treated patients who developed IgG ADA compared to those who did not develop IgG ADA (73% versus 44%) <content styleCode="italics">[see <linkHtml href="#S12.6">Clinical Pharmacology (12.6)</linkHtml> and <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>In Trial 2, one XENPOZYME-treated pediatric patient (18-months old) experienced an anaphylactic reaction during the sixth infusion and developed IgE ADA and the highest IgG ADA titers (ADA peak titer 1,600) of the patients in this trial. After treatment discontinuation, XENPOZYME was resumed four months later using a diluted drug solution and a desensitization procedure.</paragraph>
                              <paragraph>One pediatric patient (16-months old) with ASMD type A, treated with a version of olipudase alfa manufactured from a different process, experienced anaphylactic reactions (both during the fifth and sixth infusions) and developed IgG ADA (highest titer 1,600) and IgE ADA <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="54424719-5d2b-494e-844a-46031a8df8d5"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S8.1">
                     <id root="6da5d28d-7023-4b27-a53d-6431e789d734"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="9db4f0e9-f051-474a-960e-cc9e0230de01"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on findings from animal reproduction studies, XENPOZYME may cause embryo-fetal harm when administered to a pregnant female. XENPOZYME dosage initiation or escalation, at any time during pregnancy, is not recommended as it may lead to elevated sphingomyelin metabolite levels that may increase the risk of fetal malformations <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>, 											<content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>. However, the decision to continue or discontinue XENPOZYME maintenance dosing in pregnancy should consider the female's need for XENPOZYME, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal ASMD disease.</paragraph>
                              <paragraph>In an embryo-fetal toxicity study in pregnant mice, a rare malformation (exencephaly) was observed in offspring at an exposure less than the exposure at the maximum recommended human dose (MRHD) of olipudase alfa-rpcp <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>There are no available data on XENPOZYME use in pregnant females to evaluate for a drug associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Advise the pregnant female of the potential risk to the fetus.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, miscarriage, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="f5444678-ae9c-4800-9a56-c0d05e355b61"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="86800957-d73f-414f-b499-7e99c4e40b5d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study in pregnant mice, olipudase alfa-rpcp was administered intravenously at doses of 3, 10, or 30 mg/kg daily from gestation day (GD) 6 through GD 15. Exencephaly was observed in 1 litter at each of the 10 and 30 mg/kg dose groups (2 and 3 fetuses, respectively). These data are consistent with published literature reports that brief embryonic exposures to sphingomyelin metabolites or a sphingosine-1-phosphate (S1P) receptor modulator produced neural tube defects, including exencephaly, in chicks and mice.</paragraph>
                                    <paragraph>The developmental No Observed Adverse Effect Level (NOAEL) is 3 mg/kg. The AUC associated with this dose is 0.14-fold the clinical exposure at the MRHD. The developmental Lowest-Observed-Adverse-Effect Level (LOAEL), 10 mg/kg, is also associated with an exposure that is less than the clinical exposure at the MRHD.</paragraph>
                                    <paragraph>In an embryo-fetal development study in pregnant rabbits, olipudase alfa-rpcp was administered intravenously at doses of 3, 10, or 30 mg/kg daily from GD 6 through GD 19. There was no maternal or developmental toxicity. The developmental NOAEL was 30 mg/kg; the AUC<sub>0â24</sub> at this dose is approximately 10.5-fold the exposure at the MRHD.</paragraph>
                                    <paragraph>In a study of pre- and postnatal development in mice, olipudase alfa-rpcp was administered intravenously every other day from GD 6 through GD 18; then resumed every other day after parturition, from Lactation Day (LD) 1 through LD 19. Olipudase alfa-rpcp did not induce any effect on maternal reproductive function or on developmental and reproductive parameters of male and female offspring. Therefore, the maternal and developmental NOAELs are 30 mg/kg. Exposures at this dose, based on the embryo-fetal development study, were estimated to be approximately 1.5-fold the MRHD of olipudase alfa-rpcp.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="0c7ec17b-d523-4c3a-a5ab-d04e912eb58d"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="b72258bc-55a7-4560-aeac-9d738f5fa8f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of olipudase alfa-rpcp in human milk, the effects on the breastfed infant, or the effects on milk production. Olipudase alfa-rpcp is present in animal milk. <content styleCode="italics">(see <linkHtml href="#data2">Data</linkHtml>)</content>. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for XENPOZYME and any potential adverse effects on the breastfed infant from XENPOZYME or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data2">
                           <id root="549a211d-1136-4a32-a476-8179dd32561e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Olipudase alfa-rpcp was administered as a single intravenous dose (3 mg/kg) to lactating CD1 mice on post-partum day 7. Milk was not evaluated until post-partum day 9, at which time concentrations of olipudase alfa-rpcp detected were approximately 1.3% the estimated maximal maternal plasma concentration.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="38103a9f-d3f8-40ff-a93a-c6c9e713131a"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>XENPOZYME may cause embryo-fetal harm when administered during the first trimester of pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="a4f89d9d-ea62-413f-a5bf-672936bd66bc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify the pregnancy status in females of reproductive potential prior to initiating XENPOZYME.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ed3f477c-10c4-43b5-8a3e-05bdd3150afe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="82595bf9-b1fe-4ec1-a317-22cac7c24e85"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if XENPOZYME is discontinued.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="90004073-e713-460d-8485-3501ba81dcf6"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of XENPOZYME for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) have been established in pediatric patients down to birth.</paragraph>
                        <paragraph>Use of XENPOZYME for this indication is supported by evidence from an adequate, and well-controlled trial (Trial 1) in adults with supportive efficacy, safety, and tolerability data in pediatric patients (Trial 2 and Trial 3) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14.2">Clinical Studies (14.2</linkHtml>, <linkHtml href="#S14.3">14.3</linkHtml>, <linkHtml href="#S14.4">14.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>Compared to adults, a higher percentage of pediatric patients experienced treatment related serious adverse reactions, anaphylaxis, hypersensitivity reactions, and IARs that occurred within 24 hours of infusion <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Two pediatric patients, an 18 month old receiving XENPOZYME and a 16 month old with ASMD type A that received a version of olipudase alfa manufactured from a different process developed anaphylaxis <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="41af9b95-cd9f-49a1-a5c3-f54925233402"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of XENPOZYME-treated adult patients in these trials, 1 (3%) was 65 to 74 years of age, and none were 75 years of age and older <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>Clinical trials of XENPOZYME did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="6d79642d-d8c0-4b60-9789-85f35a43615e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Cases of overdosage with XENPOZYME have been reported in pediatric patients during dose escalation. Some patients experienced serious adverse reactions including death within 24 hours of initial dose <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. The clinical findings included fever, hypotension, gastrointestinal bleeding, marked elevation in liver tests, metabolic acidosis, respiratory failure, and vomiting.</paragraph>
                  <paragraph>There is no known specific antidote for XENPOZYME overdosage. In the event of overdosage, immediately stop the infusion, and monitor the patient closely in a hospital setting for the development of hypersensitivity reactions and IARs including acute phase reactions. For the management of adverse reactions, <content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                     </content>.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="1ce846e0-a665-4fbc-a169-451f8027e447"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Olipudase alfa-rpcp is a hydrolytic lysosomal sphingomyelin-specific enzyme consisting of 570 amino acids produced in a Chinese hamster ovary cell line by recombinant DNA technology. The molecular weight of olipudase alfa-rpcp is approximately 76 kDa.</paragraph>
                  <paragraph>XENPOZYME (olipudase alfa-rpcp) for injection is supplied as a sterile, preservative-free,  white to off-white lyophilized powder for reconstitution and dilution to be administered via intravenous infusion. XENPOZYME is supplied in single-dose vials.</paragraph>
                  <paragraph>Each 4 mg vial contains 4 mg olipudase alfa-rpcp, dibasic sodium phosphate (0.89 mg), methionine (14.92 mg), monobasic sodium phosphate (1.63 mg), and sucrose (50 mg). After reconstitution with 1.1 mL of Sterile Water for Injection, USP, the final concentration is 4 mg/mL <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]</content>.</paragraph>
                  <paragraph>Each 20 mg vial contains 20 mg olipudase alfa-rpcp, dibasic sodium phosphate (4.47 mg), methionine (74.6 mg), monobasic sodium phosphate (8.17 mg), and sucrose (250 mg). After reconstitution with 5.1 mL of Sterile Water for Injection, USP, the final concentration is 4 mg/mL <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]</content>.</paragraph>
                  <paragraph>The pH is 6.5 after reconstitution.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="7ebb0f65-afe4-4590-8337-126e0dd06e62"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S12.1">
                     <id root="f5f3a236-f5d8-426c-8951-f90e82c17d89"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>ASMD is a lysosomal storage disease that results from reduced activity of the enzyme acid sphingomyelinase (ASM), caused by pathogenic variants in the sphingomyelin phosphodiesterase 1 gene. ASM degrades sphingomyelin to ceramide and phosphocholine. The deficiency of ASM causes an intra-lysosomal accumulation of sphingomyelin (as well as cholesterol and other cell membrane lipids) in various tissues. XENPOZYME provides an exogenous source of ASM.</paragraph>
                        <paragraph>XENPOZYME is not expected to cross the blood-brain barrier or modulate the CNS manifestations of ASMD.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="9d4fa037-3dcf-4b10-9ebb-da7433bee10c"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="e31a3c2f-9c2f-437f-8d56-411b3b2b5bb5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Plasma Ceramide Levels</content>
                              </paragraph>
                              <paragraph>Ceramide is elevated in plasma of adult and pediatric patients with ASMD. Plasma ceramide levels showed a transient increase after each administration (post infusion) of XENPOZYME. In the dose escalation phase, plasma ceramide levels were substantially increased compared to the baseline level. Plasma ceramide levels gradually decreased following repeated administration of XENPOZYME and the pre-infusion levels were generally lower than the baseline level during the maintenance phase of treatment.</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>In adult patients with ASMD in Trial 1 <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>, the mean (standard deviation, SD) pre-infusion plasma ceramide concentration was 3.7 (1.4) mg/L at baseline and decreased to 2.2 (0.6) mg/L at Week 52 following treatment with XENPOZYME.</item>
                                 <item>In pediatric patients with ASMD in Trial 2 <content styleCode="italics">[see <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>, the mean (SD) pre-infusion plasma ceramide concentration was 4.7 (0.9) mg/L at baseline and decreased to 1.8 (0.3) mg/L at Week 52 following treatment with XENPOZYME.</item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6c357a4c-6c12-4f89-8d01-1e4beca2ed28"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Plasma Lysosphingomyelin Levels</content>
                              </paragraph>
                              <paragraph>Lysosphingomyelin is substantially elevated in plasma of adult and pediatric patients with ASMD. Plasma lysosphingomyelin levels decreased after repeated administration of XENPOZYME.</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>In adult patients with ASMD in Trial 1 <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>, the mean (SD) pre-infusion plasma lysosphingomyelin concentration was 379 (204) mcg/L at baseline and decreased to 99 (118) mcg/L at Week 52 following treatment with XENPOZYME.</item>
                                 <item>In pediatric patients with ASMD in Trial 2 <content styleCode="italics">[see <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>, the mean (SD) pre-infusion plasma lysosphingomyelin concentration was 625 (339) mcg/L at baseline and decreased to 80 (47) mcg/L at Week 52 following treatment with XENPOZYME. </item>
                              </list>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="524e9854-872f-4e79-8826-2ce2540acd6a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Liver Sphingomyelin Content</content>
                              </paragraph>
                              <paragraph>In adult patients, the liver sphingomyelin content, as assessed by histopathology, decreased from baseline to Week 52 in the XENPOZYME treatment group compared to an increase in the placebo group.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="692dbde1-8dbb-4424-b57b-8719a626691b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>In adult patients with ASMD, the mean (SD) maximum plasma olipudase alfa-rpcp concentration (C<sub>max</sub>) and area under the concentration-time curve (AUC) at steady state were 30 (5) mcg/mL and 607 (120) mcgâh/mL, respectively, at the recommended maintenance dose of 3 mg/kg administered once every 2 weeks. Olipudase alfa-rpcp C<sub>max</sub> and AUC increase proportionally over a dose range of 0.1 to 3 mg/kg (0.03 to 1 times the approved recommended maintenance dose).</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="5fa81837-3082-46e8-8275-baffb7dc868f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean (SD) volume of distribution of olipudase alfa-rpcp was 13 (2) L in adult patients with ASMD.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9729bf24-6188-490e-9733-9b6e1295a268"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The mean (SD) clearance of olipudase alfa-rpcp was 0.33 (0.07) L/h and the mean half-life (t<sub>1/2</sub>) ranged from 32 to 38 hours in adult patients with ASMD.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="e0499858-45ad-431d-a59a-ca642c213753"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>The metabolic pathway of olipudase alfa-rpcp has not been characterized. Olipudase alfa-rpcp is expected to be metabolized into small peptides and amino acids via catabolic pathways.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="74064d98-f856-49b0-9a4c-080c419b702b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                           <component>
                              <section>
                                 <id root="774fec7e-8232-4e7b-88ae-095c0d9dbf85"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>In pediatric patients (1.5 to 17.5 years of age) with ASMD, the mean (SD) C<sub>max</sub> was 24.3 (2.8) mcg/mL and the mean (SD) AUC was 449 (70) mcgâh/mL at the recommended maintenance dose of 3 mg/kg administered once every 2 weeks.</paragraph>
                                 </text>
                                 <effectiveTime value="20241224"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="691665de-3aa4-463c-8f08-b07290e10300"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6	Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of olipudase alfa-rpcp or of other olipudase alfa products.</paragraph>
                        <paragraph>Following 0.4 to 3.7 years of XENPOZYME treatment in Trial 1 <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>, 9 out of 30 (30%) XENPOZYME-treated adult patients with ASMD developed anti-olipudase alfa-rpcp IgG antibodies (referred to as IgG ADA). The median time to seroconversion from first XENPOZYME infusion was approximately 8 weeks. One out of these 9 (11%) adult patients had neutralizing antibodies (NAb) that inhibited the olipudase alfa-rpcp enzyme activity. None of these 9 patients had NAb that inhibit the cellular uptake of olipudase alfa-rpcp.</paragraph>
                        <paragraph>Following 2.5 to 3.2 years of XENPOZYME treatment in Trial 2 and 3 <content styleCode="italics">[see <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>, 6 out of 8 (75%) XENPOZYME-treated pediatric patients with ASMD developed IgG ADA. The median time to seroconversion from first XENPOZYME infusion was 10 weeks. One out of the 6 (17%) pediatric patients developed NAb that inhibited olipudase alfa-rpcp enzyme activity. None of these 6 patients had NAb that inhibited the cellular uptake of olipudase alfa-rpcp. </paragraph>
                        <paragraph>Infusion-associated reactions (including hypersensitivity reactions) occurred in a higher percentage in XENPOZYME-treated patients who developed ADA compared to those who did not develop ADA <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>There was no identified clinically significant effect of ADA on pharmacokinetics of XENPOZYME.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="cc8d32c6-b739-4962-a879-0ebf997ac084"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S13.1">
                     <id root="570200a8-b271-4719-bbf9-1eed31beb49b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241224"/>
                     <component>
                        <section>
                           <id root="8706fc7c-49e9-4753-ad7b-688bbf189a18"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Studies to evaluate the carcinogenic potential of olipudase alfa-rpcp have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="66137691-f89a-40b5-a350-d5b3eba2b606"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Studies to evaluate the mutagenic potential of olipudase alfa-rpcp have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fe0fbe0b-1b2b-449e-8a41-cdd60f2e6950"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Intravenous administration of olipudase alfa-rpcp every other day at doses up to 30 mg/kg had no adverse effects in a combined study of fertility in male and female mice. Exposures at this dose, based on the embryo-fetal development study, were estimated to be approximately 1.5-fold those of the MRHD of olipudase alfa-rpcp.</paragraph>
                           </text>
                           <effectiveTime value="20241224"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="e632164d-9151-4197-938b-e7be46e4fe1e"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In acid sphingomyelinase knockout (ASMKO) mice (a disease model of ASMD), mortality was observed after a single dose â¥10 mg/kg administered as an IV bolus injection. Observations (lethargy, coolness to touch, and unwillingness to move), combined with the adrenal hemorrhage, suggested that hypotensive shock may be the cause of death. These findings were accompanied by necrosis and apoptosis in the liver and adrenal gland, elevations of ceramide, sphingosine and sphingosine 1-phosphate in the serum, catabolites of accumulated sphingomyelin as well as elevations in the serum concentrations of inflammatory mediators, such as cytokines and acute phase proteins.</paragraph>
                        <paragraph>In ASMKO mice, a dose-dependent reduction in heart rate accompanied by a decrease in motor activity and followed by a slow decline in blood pressure was noted after a single IV administration at 3, 10, and 20 mg/kg. After 2 doses of olipudase alfa-rpcp at 3 and 10 mg/kg to ASMKO mice, a slight decline in heart rate was noted following the second administration.</paragraph>
                        <paragraph>Repeated dose studies in adult ASMKO mice show that administration of olipudase alfa-rpcp via a dose escalation regimen, (3 mg/kg administered IV every other day, followed by a single IV dose of 20 mg/kg 3 days later) did not result in toxicity. The lack of adverse findings in BALB/c, C57BL/6 mice, rats, dogs, and monkeys at comparable olipudase alfa-rpcp doses suggested that the dose-related toxicity observed in ASMKO mice may be due to the rate and amount of substrate degradation.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="e2acc974-23a1-45e5-86ae-dc1d724d5683"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section ID="S14.1">
                     <id root="87db5e86-4598-46d4-a6a6-5f3f0817f5ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 	Overview of Clinical Trials</title>
                     <text>
                        <paragraph>The efficacy of XENPOZYME for the treatment of nonâcentral nervous system manifestations of acid sphingomyelinase deficiency (ASMD) has been evaluated in 3 clinical trials involving a total of 61 patients with ASMD: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Trial 1 in adult patients (NCT02004691),</item>
                           <item>Trial 2 in pediatric patients (NCT02292654), and</item>
                           <item>Trial 3 a long-term trial in pediatric patients (NCT02004704).</item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="7589cc52-4d63-4628-ad4c-ab719b61bc9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 	Clinical Trial in Adult Patients with ASMD</title>
                     <text>
                        <paragraph>Trial 1 was a multicenter, randomized, double-blinded, placebo-controlled, repeat-dose phase II/III trial in adult patients with ASMD (clinical diagnosis consistent with ASMD type B and A/B). In this trial, patients received either XENPOZYME or placebo. Treatment was administered in both groups as an intravenous infusion once every 2 weeks. XENPOZYME was dosed as follows: 0.1 mg/kg (Day 1, Week 0), 0.3 mg/kg (Weeks 2 and 4), 0.6 mg/kg (Weeks 6 and 8), 1 mg/kg (Week 10), 2 mg/kg (Week 12), and then a maintenance dose of 3 mg/kg (Week 14 onwards). The trial was divided into 2 consecutive periods: a randomized placebo-controlled, double-blinded primary analysis period (PAP) which lasted to Week 52, followed by an extension treatment period (ETP) for up to 4 years. Patients randomized to the placebo arm in the PAP crossed over to receive XENPOZYME treatment in the ETP to reach the targeted dose of 3 mg/kg, while patients in the original XENPOZYME arm continued treatment.</paragraph>
                        <paragraph>Patients enrolled in the trial had a diffusion capacity of the lungs for carbon monoxide (DLco) â¤70% of the predicted normal value and a spleen volume â¥6 multiples of normal (MN) measured by magnetic resonance imaging (MRI). The trial population included 87% White, 7% Asian, and 7% other; for ethnicity, 32% identified as Hispanic/Latino, 65% as non-Hispanic/Latino, and 3% were not reported.</paragraph>
                        <paragraph>Five males and 13 females with a median age of 34 years (range: 18 to 66) were included in the placebo arm and 8 males and 5 females with a median age of 34 years (range: 20 to 59) were included in the XENPOZYME arm. The XENPOZYME and placebo groups included 1 patient (8%) and 2 patients (11%) with mild renal impairment (60 mL/minute â¤ creatinine clearance &lt;90 mL/minute), respectively. There were no patients with moderate or severe renal impairment.</paragraph>
                        <paragraph>Key efficacy endpoints included assessment of % predicted DLco, spleen volume, liver volume, and platelet count.</paragraph>
                        <paragraph>At Week 52 during the PAP, an increase of 21% in the mean percent change in % predicted DLco was observed in the XENPOZYME-treated patients compared to the placebo-treated patients (Table 9). A reduction in spleen volume of 39% was observed in the XENPOZYME-treated patients compared to the placebo-treated patients. The changes in % predicted DLco and spleen volume were noted at Week 26 of treatment, the first post-dose endpoint assessment (Figures 1 and 2).</paragraph>
                        <paragraph>A decrease in mean liver volume and an increase in mean platelet count were noted in the XENPOZYME-treated patients compared to the placebo-treated patients at Week 52 (Table 9).</paragraph>
                        <table width="90%" ID="table9">
                           <caption>Table 9: Observed Value and Percentage Change from Baseline to Week 52 in Key Endpoints in Adult Patients with ASMD Type B, A/B on XENPOZYME or Placebo (Trial 1)</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="15%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="15%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Placebo</th>
                                 <th styleCode="Rrule">XENPOZYME</th>
                                 <th styleCode="Rrule">Difference<br/>[95% CI]</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4">Nominal p value:</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">DLco</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">18</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean % predicted DLco at baseline (SD)</td>
                                 <td styleCode="Rrule">48.5 (10.8)</td>
                                 <td styleCode="Rrule">49.1 (9.7)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean % predicted DLco at Week 52 (SD)</td>
                                 <td styleCode="Rrule">49.9 (11.1)</td>
                                 <td styleCode="Rrule">59.4 (9.6)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in % predicted DLco at Week 52 (SE)</td>
                                 <td styleCode="Rrule">3.0 (3.3)</td>
                                 <td styleCode="Rrule">23.9 (3.8)</td>
                                 <td styleCode="Rrule">20.9 (5.0)<footnote>p value = 0.0003;</footnote>
                                    <br/>[10.6, 31.2]</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Spleen volume </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">18</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Spleen Volume (MN) at baseline (SD)</td>
                                 <td styleCode="Rrule">11.2 (3.8)</td>
                                 <td styleCode="Rrule">11.5 (4.7)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Spleen Volume (MN) at Week 52 (SD)</td>
                                 <td styleCode="Rrule">11.2 (4.2)</td>
                                 <td styleCode="Rrule">7.2 (3.9)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in Spleen Volume (in MN) at Week 52 (SE)</td>
                                 <td styleCode="Rrule">0.5 (2.62)</td>
                                 <td styleCode="Rrule">-38.9 (3.0)</td>
                                 <td styleCode="Rrule">-39.4 (4.0)<footnote ID="t9f1">p value &lt;0.0001;</footnote>
                                    <br/>[-47.6, -31.2]</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Liver volume</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">18</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Liver Volume (MN) at baseline (SD)</td>
                                 <td styleCode="Rrule">1.6 (0.5)</td>
                                 <td styleCode="Rrule">1.4 (0.3)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Liver Volume (MN) at Week 52 (SD)</td>
                                 <td styleCode="Rrule">1.6 (0.5)</td>
                                 <td styleCode="Rrule">1.0 (0.2)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in Liver Volume from baseline to Week 52 (SE)</td>
                                 <td styleCode="Rrule">-1.8 (2.7)</td>
                                 <td styleCode="Rrule">-26.5 (3.2)</td>
                                 <td styleCode="Rrule">-24.7 (4.2)<footnoteRef IDREF="t9f1"/>
                                    <br/>[-33.4, -16.1]</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Platelet count</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">18</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Mean Platelet Count (10<sup>9</sup>/L) at baseline (SD)</td>
                                 <td styleCode="Rrule">115.6 (36.3)</td>
                                 <td styleCode="Rrule">109.3 (30.6)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">16</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Mean Platelet Count (10<sup>9</sup>/L) at Week 52 (SD)</td>
                                 <td styleCode="Rrule">120.2 (43.2)</td>
                                 <td styleCode="Rrule">126.4 (29.0)</td>
                                 <td styleCode="Rrule">NA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">n</td>
                                 <td styleCode="Rrule">16</td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in Platelet Count from baseline to Week 52 (SE)</td>
                                 <td styleCode="Rrule">2.7 (4.5)</td>
                                 <td styleCode="Rrule">18.3 (5.0)</td>
                                 <td styleCode="Rrule">+15.6 (6.7) <footnote>p value= 0.0280</footnote>
                                    <br/>[1.8, 29.4]</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Seventeen of 18 patients previously receiving placebo and 13 of 13 patients previously treated with XENPOZYME for 52 weeks (in the PAP) started or continued treatment with XENPOZYME, respectively, for up to 4 years. At Week 104, patients initially randomized to placebo had received XENPOZYME for 52 weeks and demonstrated the following LS mean (SE) percent changes in clinical parameters from baseline (before first administration of XENPOZYME): increase in % predicted DLco was 26.8% (6.2) (Figure 1); reduction in spleen volume (MN) was 36.5% (2.5) (Figure 2); reduction in liver volume (MN) was 29.5 (2.6); and increase in platelet count was 19.5 (6.7).</paragraph>
                        <paragraph>Patients in the previous XENPOZYME group demonstrated improvement from baseline to Week 104 in the following parameters: LS mean (SE) percent increase in % predicted DLco was 34.1% (7.9) (Figure 1); LS mean (SE) percent reduction in spleen volume (MN) was 48.3 (2.9) (Figure 2); LS mean (SE) percent reduction in liver volume (MN) was 31.7 (2.9); LS mean (SE) percent increase in platelet count was 24.0 (8.2).</paragraph>
                        <paragraph ID="fig1">
                           <content styleCode="bold">Figure 1: Plot of the LS Means (95% CI) of the Percentage Change in DLco (% predicted) from Baseline to Week 104 in Adult Patients with ASMD (Trial 1)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM1"/>
                        </paragraph>
                        <paragraph>The vertical bars represent the 95% CIs for the LS means.</paragraph>
                        <paragraph>The LS means and 95% CIs are based on a mixed model for repeated measures approach, using data up to Week 104. Patients in placebo/XENPOZYME group received placebo by Week 52 and switched to XENPOZYME thereafter.</paragraph>
                        <paragraph ID="fig2">
                           <content styleCode="bold">Figure 2: Plot of the LS Means (95% CI) of the Percentage Change in Spleen Volume (MN) from Baseline to Week 104 in Patients with ASMD (Trial 1)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                        <paragraph>The vertical bars represent the 95% CIs for the LS means.</paragraph>
                        <paragraph>The LS means and 95% CIs are based on a mixed model for repeated measures approach, using data up to Week 104. Patients in placebo/XENPOZYME group received placebo by Week 52 and switched to XENPOZYME thereafter.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="xenpozyme-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="xenpozyme-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="a1ce38db-0872-465d-ba4a-094dc222dd46"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 	Clinical Trial in Pediatric Patients with ASMD</title>
                     <text>
                        <paragraph>Trial 2 was a multi-center, open-label, repeated-dose trial of XENPOZYME administered intravenously once every 2 weeks (via infusion) for 64 weeks in pediatric patients aged &lt;18 years with a clinical diagnosis consistent with ASMD type B and A/B. Exploratory efficacy endpoints related to organomegaly, pulmonary and liver functions, and linear growth were evaluated at Week 52. XENPOZYME was dosed as follows: 0.03 mg/kg (Day 1, Week 0), 0.1 mg/kg (Weeks 2), 0.3 mg/kg (Weeks 4 and 6), 0.6 mg/kg (Week 8 and 10), 1 mg/kg (Week 12), 2 mg/kg (Week 14), and then a maintenance dose of 3 mg/kg (Week 16 onwards).</paragraph>
                        <paragraph>In Trial 2, 8 patients (7 patients from 2 to &lt;12 years old, and 1 patient &lt;2 years old) received an initial dose of 0.03 mg/kg XENPOZYME and all but one completed the dose escalation up to the maintenance dose of 3 mg/kg within 22 weeks. All patients were White and of non-Hispanic/Latino ethnicity.</paragraph>
                        <paragraph>Patients enrolled in the trial had a spleen volume â¥5 MN measured by MRI. Age of patients treated with XENPOZYME ranged from 1 to 10 years old, with both sexes equally represented.</paragraph>
                        <paragraph>Treatment with XENPOZYME resulted in improvements in mean percent change in % predicted DLco, spleen and liver volumes, platelet counts, and linear growth progression (as measured by height Z-scores) at Week 52 as compared to baseline (Table 10).</paragraph>
                        <table width="90%" ID="table10">
                           <caption>Table 10: Efficacy Results in XENPOZYME-Treated Pediatric Patients with ASMD (Trial 2)</caption>
                           <col width="60%" align="left" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Baseline Values </th>
                                 <th styleCode="Rrule">Week 52 Values</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">(n=3)</td>
                                 <td styleCode="Rrule">(n=3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean % predicted DLco (SD)</td>
                                 <td styleCode="Rrule">48.5 (8.1)</td>
                                 <td styleCode="Rrule">70.9 (13.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in % predicted DLco* (SE)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">45.9 (22.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% CI</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-12.5, 104.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">(n=8)</td>
                                 <td styleCode="Rrule">(n=8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Spleen Volume (MN) (SD)</td>
                                 <td styleCode="Rrule">18.3 (5.6)</td>
                                 <td styleCode="Rrule">9.50 (2.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in Spleen Volume (in MN) (SE)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-46.7 (3.6) </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% CI</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-55.5, -37.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">(n=8)</td>
                                 <td styleCode="Rrule">(n=8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Liver Volume (MN) (SD)</td>
                                 <td styleCode="Rrule">2.5 (0.5)</td>
                                 <td styleCode="Rrule">1.6 (0.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in Liver Volume (in MN) (SE)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-38.1 (2.9)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% CI</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">-44.1, -32.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">(n=8)</td>
                                 <td styleCode="Rrule">(n=7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Platelet Count (10<sup>9</sup>/L) (SD)</td>
                                 <td styleCode="Rrule">136.7 (33.2)</td>
                                 <td styleCode="Rrule">184.5 (54.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">LS Mean Percent change in Platelet Count (SE)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">37.6 (13.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% CI</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">8.5, 66.7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">(n=8)</td>
                                 <td styleCode="Rrule">(n=7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean height Z-scores (SD)</td>
                                 <td styleCode="Rrule">-1.9 (0.8)</td>
                                 <td styleCode="Rrule">-1.5 (1.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">LS Mean Change in height Z-scores (SE)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">0.5 (0.1)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% CI</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">0.2, 0.8</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="2f3a5c17-e156-4b7e-913f-bfd6fb0802a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 	Extension Trial in ASMD Pediatric Patients </title>
                     <text>
                        <paragraph>The 8 pediatric patients 2 to &lt;12 years of age from Trial 2 continued treatment in an open label long term trial (Trial 3) and were treated with XENPOZYME for 2.5 to 3.2 years.</paragraph>
                        <paragraph>Efficacy analyses showed continued improvements in the 3 patients evaluated for % predicted DLco, 6 patients evaluated for platelet counts, and all 8 patients evaluated for spleen and liver volumes, compared to baseline, during the additional 6 months extension. In addition, the height Z-score increased by 1.3 from baseline when evaluated through 24 months of XENPOZYME treatment. Bone age, as assessed by hand x-ray, was delayed by a mean of 26.4 months at baseline in the 7 pediatric patients enrolled in Trial 2 with a bone age measured at Month 24 in Trial 3. The bone age improved to within a mean of 12 months of the chronological age when assessed at Month 24 in these 7 patients.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="ada214be-9777-461b-899a-5aa72d026529"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section>
                     <id root="a32c3fb9-3ca6-49b8-824f-738956600e93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>XENPOZYME (olipudase alfa-rpcp) for injection is supplied as a sterile white to off-white lyophilized powder for reconstitution in a single-dose vial. XENPOZYME does not contain any preservatives.</paragraph>
                        <paragraph>XENPOZYME is available supplied as:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Carton containing one 20 mg single-dose vial (NDC 58468-0050-1)</item>
                           <item>Carton containing one 4 mg single-dose vial (NDC 58468-0051-1)</item>
                        </list>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="35ef2579-36ae-42c3-a960-af3b951c5737"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F). Do not freeze.</paragraph>
                        <paragraph>For storage of reconstituted and diluted solution <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="5dbc58f4-37f2-41b6-b0e4-0e02fbe79850"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20241224"/>
               <component>
                  <section>
                     <id root="2f2e3c12-ed09-4480-bf6b-3006670b8db1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions (Including Anaphylaxis) and Infusion-Associated Reactions (IARs)</content>
                        </paragraph>
                        <paragraph>Advise the patient and caregiver that reactions related to the infusion may occur during and after XENPOZYME treatment, including life-threatening hypersensitivity reactions, anaphylaxis, and IARs. Inform the patient and/or caregiver of the signs and symptoms of hypersensitivity reactions and IARs and to seek immediate medical care should signs and symptoms occur <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5cd15e56-95a7-4928-b05e-b1cb2071cb3d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>XENPOZYME may cause embryo-fetal harm. Advise the pregnant female and females of reproductive potential of the potential risk to the fetus. Advise a female patient and caregiver to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise a female of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if XENPOZYME is discontinued <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="54046ed9-e045-4b76-aaf5-f1f572ddd417"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>Genzyme Corporation<br/>450 Water Street<br/>Cambridge, MA 02141<br/>U.S. License Number: 1596</paragraph>
                  <paragraph>Â©2024 Sanofi. All rights reserved. XENPOZYME is a registered trademark of Genzyme Corporation.</paragraph>
               </text>
               <effectiveTime value="20241224"/>
            </section>
         </component>
         <component>
            <section>
               <id root="207377f9-e36b-4fd7-a481-364445908ef2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton</title>
               <text>
                  <paragraph>NDC 58468-0050-1<br/>Rx only</paragraph>
                  <paragraph>Xenpozymeâ¢<br/>(olipudase alfa-rpcp)</paragraph>
                  <paragraph>For injection</paragraph>
                  <paragraph>20 mg per vial</paragraph>
                  <paragraph>For Intravenous Infusion<br/>after Reconstitution<br/>and Dilution</paragraph>
                  <paragraph>1 single-dose vial<br/>Discard unused portion</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="xenpozyme-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d16e8fb8-372f-409d-9918-5be2be987c89"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 4 mg Vial Carton</title>
               <text>
                  <paragraph>NDC 58468-0051-1<br/>Rx only</paragraph>
                  <paragraph>Xenpozymeâ¢<br/>(olipudase alfa-rpcp)</paragraph>
                  <paragraph>For injection</paragraph>
                  <paragraph>4 mg per vial</paragraph>
                  <paragraph>For Intravenous Infusion<br/>after Reconstitution<br/>and Dilution</paragraph>
                  <paragraph>1 single-dose vial<br/>Discard unused portion</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20241224"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 4 mg Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="xenpozyme-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>